(TER) Teradyne - Overview
Stock: Semiconductor Testers, Robotics, Wireless Testers, Circuit Board Testers
| Risk 5d forecast | |
|---|---|
| Volatility | 57.0% |
| Relative Tail Risk | -13.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.91 |
| Alpha | 154.71 |
| Character TTM | |
|---|---|
| Beta | 1.875 |
| Beta Downside | 2.103 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.18% |
| CAGR/Max DD | 0.76 |
EPS (Earnings per Share)
Revenue
Description: TER Teradyne February 11, 2026
Teradyne Inc. (NASDAQ: TER) designs, develops, manufactures and sells automated test equipment and robotics solutions worldwide, operating through three segments: Semiconductor Test, Robotics, and Other.
The Semiconductor Test segment supplies wafer-level, package-level and system-level test platforms-including the J750, Magnum and ETS systems-to integrated device manufacturers, fabless companies, foundries and test subcontractors across automotive, industrial, communications, consumer and cloud applications. In FY 2023 the segment generated $2.1 billion in revenue, up 5% YoY, driven by rising demand for AI-chip and automotive-electronics testing.
The Robotics segment offers collaborative arms, autonomous mobile robots and advanced control software for manufacturing and logistics customers, as well as the LitePoint wireless test portfolio. Robotics revenue grew 15% YoY to $620 million in FY 2023, reflecting accelerating automation in e-commerce fulfillment and supply-chain resilience initiatives.
Key macro drivers include the global surge in semiconductor fab capacity (estimated 7% CAGR through 2028) and the broader shift toward factory automation, both of which underpin Teradyne’s growth outlook. As of Q1 2024 the company posted a non-GAAP operating margin of 12.3% and a backlog of $1.2 billion, indicating strong order flow.
For a data-driven valuation, see ValueRay’s detailed model.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 554.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -1.98 > 1.0 |
| NWC/Revenue: 26.15% < 20% (prev 42.26%; Δ -16.12% < -1%) |
| CFO/TA 0.16 > 3% & CFO 674.4m > Net Income 554.0m |
| Net Debt (53.4m) to EBITDA (779.7m): 0.07 < 3 |
| Current Ratio: 1.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (157.7m) vs 12m ago -3.39% < -2% |
| Gross Margin: 58.32% > 18% (prev 0.58%; Δ 5774 % > 0.5%) |
| Asset Turnover: 80.98% > 50% (prev 76.03%; Δ 4.94% > 0%) |
| Interest Coverage Ratio: 81.33 > 6 (EBITDA TTM 779.7m / Interest Expense TTM 8.02m) |
Altman Z'' 5.10
| A: 0.20 (Total Current Assets 1.94b - Total Current Liabilities 1.10b) / Total Assets 4.17b |
| B: 0.16 (Retained Earnings 686.8m / Total Assets 4.17b) |
| C: 0.17 (EBIT TTM 652.5m / Avg Total Assets 3.94b) |
| D: 2.03 (Book Value of Equity 2.80b / Total Liabilities 1.37b) |
| Altman-Z'' Score: 5.10 = AAA |
Beneish M -2.55
| DSRI: 1.45 (Receivables 773.6m/471.4m, Revenue 3.19b/2.82b) |
| GMI: 1.00 (GM 58.32% / 58.48%) |
| AQI: 1.07 (AQ_t 0.38 / AQ_t-1 0.35) |
| SGI: 1.13 (Revenue 3.19b / 2.82b) |
| TATA: -0.03 (NI 554.0m - CFO 674.4m) / TA 4.17b) |
| Beneish M-Score: -2.55 (Cap -4..+1) = A |
What is the price of TER shares?
Over the past week, the price has changed by +14.72%, over one month by +38.63%, over three months by +73.63% and over the past year by +180.07%.
Is TER a buy, sell or hold?
- StrongBuy: 9
- Buy: 2
- Hold: 4
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the TER price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 302.7 | -2.7% |
| Analysts Target Price | 302.7 | -2.7% |
| ValueRay Target Price | 343.4 | 10.4% |
TER Fundamental Data Overview February 12, 2026
P/E Forward = 52.6316
P/S = 16.0294
P/B = 17.0789
P/EG = 1.7568
Revenue TTM = 3.19b USD
EBIT TTM = 652.5m USD
EBITDA TTM = 779.7m USD
Long Term Debt = 127.8m USD (estimated: total debt 347.1m - short term 219.3m)
Short Term Debt = 219.3m USD (from shortTermDebt, last quarter)
Debt = 347.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 53.4m USD (from netDebt column, last quarter)
Enterprise Value = 51.16b USD (51.13b + Debt 347.1m - CCE 322.0m)
Interest Coverage Ratio = 81.33 (Ebit TTM 652.5m / Interest Expense TTM 8.02m)
EV/FCF = 113.6x (Enterprise Value 51.16b / FCF TTM 450.4m)
FCF Yield = 0.88% (FCF TTM 450.4m / Enterprise Value 51.16b)
FCF Margin = 14.12% (FCF TTM 450.4m / Revenue TTM 3.19b)
Net Margin = 17.37% (Net Income TTM 554.0m / Revenue TTM 3.19b)
Gross Margin = 58.32% ((Revenue TTM 3.19b - Cost of Revenue TTM 1.33b) / Revenue TTM)
Gross Margin QoQ = 57.49% (prev 58.41%)
Tobins Q-Ratio = 12.27 (Enterprise Value 51.16b / Total Assets 4.17b)
Interest Expense / Debt = 1.04% (Interest Expense 3.62m / Debt 347.1m)
Taxrate = 10.18% (29.2m / 286.4m)
NOPAT = 586.0m (EBIT 652.5m * (1 - 10.18%))
Current Ratio = 1.76 (Total Current Assets 1.94b / Total Current Liabilities 1.10b)
Debt / Equity = 0.12 (Debt 347.1m / totalStockholderEquity, last quarter 2.80b)
Debt / EBITDA = 0.07 (Net Debt 53.4m / EBITDA 779.7m)
Debt / FCF = 0.12 (Net Debt 53.4m / FCF TTM 450.4m)
Total Stockholder Equity = 2.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.06% (Net Income 554.0m / Total Assets 4.17b)
RoE = 19.88% (Net Income TTM 554.0m / Total Stockholder Equity 2.79b)
RoCE = 22.38% (EBIT 652.5m / Capital Employed (Equity 2.79b + L.T.Debt 127.8m))
RoIC = 21.05% (NOPAT 586.0m / Invested Capital 2.78b)
WACC = 12.74% (E(51.13b)/V(51.48b) * Re(12.82%) + D(347.1m)/V(51.48b) * Rd(1.04%) * (1-Tc(0.10)))
Discount Rate = 12.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.38%
[DCF Debug] Terminal Value 63.14% ; FCFF base≈459.9m ; Y1≈468.6m ; Y5≈515.2m
Fair Price DCF = 29.58 (EV 4.69b - Net Debt 53.4m = Equity 4.63b / Shares 156.6m; r=12.74% [WACC]; 5y FCF grow 1.70% → 2.90% )
EPS Correlation: -1.74 | EPS CAGR: 17.60% | SUE: 4.0 | # QB: 2
Revenue Correlation: 13.53 | Revenue CAGR: 10.09% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=2.11 | Chg30d=+0.884 | Revisions Net=+13 | Analysts=15
EPS current Year (2026-12-31): EPS=6.27 | Chg30d=+1.091 | Revisions Net=+12 | Growth EPS=+58.3% | Growth Revenue=+31.5%
EPS next Year (2027-12-31): EPS=8.03 | Chg30d=+1.372 | Revisions Net=+12 | Growth EPS=+28.0% | Growth Revenue=+18.4%